Fullgreen Sustainable Biomedicine Technology Co., Ltd. today announced the expansion of its Continuous API Process Development and CDMO services, targeting small-molecule pharmaceuticals, high-value key intermediates, N-3 intermediate platforms, and synthetic processes that face scale-up, safety, cost, or quality challenges under conventional batch manufacturing.

As the global pharmaceutical industry faces increasing pressure from supply chain instability, rising production costs, stricter quality expectations, solvent reduction goals, and the need for safer handling of hazardous reactions, continuous manufacturing is becoming a strategic technology for next-generation API and intermediate production. Compared with traditional batch processing, continuous flow chemistry enables precise control of mixing, heat transfer, residence time, pressure, reaction quenching, and process monitoring within compact reactor systems. This makes it particularly valuable for highly exothermic reactions, unstable intermediates, hazardous reagents, high-temperature or high-pressure chemistry, and multi-step synthetic sequences where batch scale-up can be difficult or risky.

Fullgreen’s new CDMO service platform is designed to support pharmaceutical companies, generic drug manufacturers, biotech companies, API suppliers, and specialty chemical producers from early feasibility assessment to process design, optimization, scale-up, and technology transfer. The service scope includes route evaluation, continuous process feasibility analysis, solvent strategy design, reactor module selection, process parameter optimization, process analytical technology planning, safety assessment, impurity pathway analysis, documentation support, and GMP manufacturing transition planning through qualified production frameworks or partners where applicable.

The company’s development focus includes, but is not limited to, oncology drugs, cardiovascular drugs, diabetes therapies, PDE5 inhibitors, Sartan intermediates, Statin side-chain platforms, C-aryl glucoside intermediates, and other high-value building blocks that may serve multiple downstream APIs. Fullgreen emphasizes that its CDMO model is not limited to simply optimizing one reaction step. Instead, the company aims to help customers identify the most commercially meaningful and technically defensible process nodes within a pharmaceutical synthesis route.

According to Fullgreen, one of the most important questions in API process development is not only whether a compound can be synthesized, but whether the selected intermediate has strong market relevance, downstream flexibility, regulatory value, cost-reduction potential, and platform applicability. Intermediates positioned three or more steps before the final API, often referred to as N-3 or upstream key intermediates, may offer strategic value because they can provide broader supply chain flexibility while still retaining significant technical barriers. When such intermediates can be used across multiple final products, they become particularly attractive candidates for continuous manufacturing platforms.

Fullgreen’s continuous API process development services are especially suitable for reaction types where process intensification can create clear technical advantages. These may include hydrogenation, nitration, halogenation, reductive amination, amidation, esterification, nucleophilic substitution, cyclization, oxidation, reduction, photochemical reactions, organometallic chemistry, and transition-metal-catalyzed coupling reactions. In many of these cases, continuous reactors can reduce the reaction hold-up volume, improve thermal control, minimize local overheating, reduce impurity formation, and increase reproducibility. For reactions involving hazardous reagents or unstable intermediates, continuous operation may also improve process safety by generating and consuming reactive species in a controlled, low-inventory environment.

A central element of Fullgreen’s service offering is the integration of Process Analytical Technology, or PAT, from the early development stage. Instead of treating analytics only as a final quality control activity, Fullgreen designs in-line or on-line monitoring strategies based on molecular structure, functional group transformation, UV absorption behavior, reaction kinetics, impurity formation, and critical quality attributes. Potential analytical tools may include UV/Vis monitoring, FTIR, Raman spectroscopy, pressure and temperature monitoring, turbidity measurement, particle-size evaluation where relevant, and offline HPLC or UPLC verification. This approach supports deeper process understanding and aligns with Quality by Design principles.

Sustainability is another major pillar of Fullgreen’s CDMO strategy. Continuous manufacturing can help reduce solvent usage, shorten reaction time, decrease energy consumption, lower waste generation, and improve overall material efficiency. Fullgreen further strengthens this value proposition by developing single-solvent or common-solvent strategies where feasible, reducing unnecessary extraction or intermediate purification steps, and improving compatibility between sequential reaction stages. For customers seeking long-term supply of high-value intermediates, modular continuous systems may provide flexible capacity expansion, improved operational consistency, and a more resilient manufacturing model.

Fullgreen also positions its service model as a bridge between research-stage synthetic chemistry and commercially relevant manufacturing. Many pharmaceutical projects fail to capture full value because early synthetic routes are designed for laboratory success rather than long-term manufacturability. Fullgreen’s approach is to evaluate manufacturability, safety, impurity control, solvent economy, raw material availability, and downstream scalability at the earliest possible stage. This allows customers to avoid late-stage process redesign and accelerate the transition from discovery or early development chemistry to a more robust production strategy.

For generic pharmaceutical companies, Fullgreen’s continuous process CDMO services may support cost competitiveness, supply chain independence, and improved process reliability for high-demand APIs or intermediates. For innovator companies and biotech developers, the service may accelerate process readiness, reduce technical uncertainty, and provide differentiated manufacturing intellectual property. For API suppliers and specialty chemical companies, Fullgreen’s platform may enable the development of higher-margin intermediate products with stronger technical barriers and broader customer applicability.

Fullgreen believes that the future of API CDMO services will be defined not only by production capacity, but by the ability to identify the right molecule, the right intermediate, and the right manufacturing strategy. By combining continuous flow process development, key intermediate platform design, PAT-based quality control, green chemistry thinking, and technology transfer planning, Fullgreen aims to help customers build more competitive, scalable, and sustainable pharmaceutical manufacturing processes.

About Fullgreen Sustainable Biomedicine Technology Co., Ltd.
Fullgreen Sustainable Biomedicine Technology Co., Ltd. is dedicated to developing advanced biomedicine and process technology platforms integrating continuous manufacturing, lipid-based delivery systems, nanotechnology, cosmetic science, pharmaceutical process development, and sustainable material innovation. The company focuses on high-value pharmaceutical intermediates, API process optimization, NLC/LNP delivery technologies, and cross-disciplinary biomedical applications, with the goal of becoming a distinctive innovation partner for pharmaceutical, biotech, and specialty formulation companies in Asia and global markets.